321 related articles for article (PubMed ID: 32775813)
1. Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events.
Herrmann SM; Perazella MA
Kidney Int Rep; 2020 Aug; 5(8):1139-1148. PubMed ID: 32775813
[TBL] [Abstract][Full Text] [Related]
2. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
Hakroush S; Kopp SB; Tampe D; Gersmann AK; Korsten P; Zeisberg M; Tampe B
Front Immunol; 2020; 11():624547. PubMed ID: 33552089
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors and acute kidney injury.
Zhou P; Gao Y; Kong Z; Wang J; Si S; Han W; Li J; Lv Z; Wang R
Front Immunol; 2024; 15():1353339. PubMed ID: 38464524
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review.
Sise ME; Seethapathy H; Reynolds KL
Oncologist; 2019 Jun; 24(6):735-742. PubMed ID: 30902916
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibitor related nephrotoxicity: Advances in clinicopathologic features, noninvasive approaches, and therapeutic strategy and rechallenge.
Miao J; Sise ME; Herrmann SM
Front Nephrol; 2022; 2():1017921. PubMed ID: 37674988
[TBL] [Abstract][Full Text] [Related]
6. Nephrotoxicity in the Age of Immune Checkpoint Inhibitors: Mechanisms, Diagnosis, and Management.
Moturi K; Sharma H; Hashemi-Sadraei N
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203586
[TBL] [Abstract][Full Text] [Related]
7. Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors.
Qin Z; Liu K; Xu X; Li T; Ge Y; Wu B; Xing C; Mao H
Future Oncol; 2022 May; 18(16):1951-1962. PubMed ID: 35232231
[TBL] [Abstract][Full Text] [Related]
8. Acute Kidney Injury Induced by Immune Checkpoint Inhibitors.
Tian R; Liang J; Li R; Zhou X
Kidney Dis (Basel); 2022 May; 8(3):190-201. PubMed ID: 35702709
[TBL] [Abstract][Full Text] [Related]
9. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
10. Comparative Risk of Renal Adverse Events in Patients Receiving Immune Checkpoint Inhibitors: A Bayesian Network Meta-Analysis.
Liu K; Qin Z; Xu X; Li T; Ge Y; Mao H; Xing C
Front Oncol; 2021; 11():662731. PubMed ID: 34221977
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events.
Isik B; Alexander MP; Manohar S; Vaughan L; Kottschade L; Markovic S; Lieske J; Kukla A; Leung N; Herrmann SM
Kidney Int Rep; 2021 Apr; 6(4):1022-1031. PubMed ID: 33912752
[TBL] [Abstract][Full Text] [Related]
12. Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study.
Zhou P; Liu B; Shen N; Fan X; Lu S; Kong Z; Gao Y; Lv Z; Wang R
Ren Fail; 2024 Dec; 46(1):2326186. PubMed ID: 38466161
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitor-Associated AKI: Debates in Diagnosis, Management, and Rechallenge.
Seethapathy H; Herrmann SM; Rashidi A
Semin Nephrol; 2022 Nov; 42(6):151346. PubMed ID: 37137187
[TBL] [Abstract][Full Text] [Related]
14. Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy: Single Center Experience of Management and Drug Rechallenge.
Manohar S; Ghamrawi R; Chengappa M; Goksu BNB; Kottschade L; Finnes H; Dronca R; Leventakos K; Herrmann J; Herrmann SM
Kidney360; 2020 Jan; 1(1):16-24. PubMed ID: 35372854
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint inhibitor therapy-associated acute kidney injury: time to move on to evidence-based recommendations.
Perazella MA; Sprangers B
Clin Kidney J; 2021 May; 14(5):1301-1306. PubMed ID: 33970161
[TBL] [Abstract][Full Text] [Related]
16. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents.
Suzman DL; Pelosof L; Rosenberg A; Avigan MI
Liver Int; 2018 Jun; 38(6):976-987. PubMed ID: 29603856
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitor-Associated Nephrotoxicity.
Mamlouk O; Danesh FR
Nephron; 2024; 148(1):11-15. PubMed ID: 37257429
[TBL] [Abstract][Full Text] [Related]
18. Compartmentalization of Intrarenal Programmed Cell Death Protein 1-Ligand 1 and Its Receptor in Kidney Injury Related to Immune Checkpoint Inhibitor Nephrotoxicity.
Tampe D; Kopp SB; Baier E; Hakroush S; Tampe B
Front Med (Lausanne); 2022; 9():902256. PubMed ID: 35755033
[TBL] [Abstract][Full Text] [Related]
19. Renal Complications Related to Checkpoint Inhibitors: Diagnostic and Therapeutic Strategies.
Belliere J; Mazieres J; Meyer N; Chebane L; Despas F
Diagnostics (Basel); 2021 Jun; 11(7):. PubMed ID: 34208848
[TBL] [Abstract][Full Text] [Related]
20. Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors.
Seethapathy H; Zhao S; Strohbehn IA; Lee M; Chute DF; Bates H; Molina GE; Zubiri L; Gupta S; Motwani S; Leaf DE; Sullivan RJ; Rahma O; Blumenthal KG; Villani AC; Reynolds KL; Sise ME
Kidney Int Rep; 2020 Oct; 5(10):1700-1705. PubMed ID: 33102962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
